Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results